Printer Friendly

MEDCO RESEARCH'S ADENOCARD DRUG IS APPROVED FOR MARKETING IN SEVEN EUROPEAN COUNTRIES

 RESEARCH TRIANGLE PARK, N.C., Aug. 12 /PRNewswire/ -- Medco Research, Inc. (AMEX: MRE) today announced that its European manufacturing and marketing licensee for Adenocard(R), Sanofi-Winthrop, has received Committee for Proprietary Medicinal Products (CPMP) approval to market the product under the name Adenocor(R) in France, Belgium, The Netherlands, Luxembourg, Spain, Greece and Portugal.
 Adenocor is an intravenous formulation of adenosine used in restoring normal sinus rhythm in patients experiencing paroxysmal supraventricular tachycardia (PSVT), periodic episodes of abnormally rapid heart beats that originate in the heart's upper chambers. In addition to restoring natural heartbeat rhythm, Adenocor is effective in enhancing the diagnostic capability of ECG (electrocardiography) in determining whether a PSVT originates in the upper chambers of the heart. The American Heart Association has classified Adenocard as first-line therapy for acute treatment of PSVT.
 In Europe, Adenocard is currently being marketed by Sanofi-Winthrop in the United Kingdom (under the trade name Adenocor) and Switzerland (under the trade name Krenosin(R)) and will be launched in the seven additional countries early in 1994.
 "We are obviously pleased with the new approval of Adenocor in these seven European countries, and look forward to future approvals in other countries in the world," said Archie W. Prestayko, Ph.D., president and chief executive officer of Medco Research. "While our Adenocard product has gained broad acceptance in the U.S. market during the past three years, it is also gratifying to find it increasingly accepted throughout the world in its application as first-line treatment of certain cardiac arrhythmias."
 Medco Research is a pharmaceutical company engaged in the acquisition, research and development of new prescription drugs for the diagnosis or treatment of certain cardiovascular diseases and cancer.
 -0- 8/12/93
 /CONTACT: James F. Mohar of Medco Research, Inc., 919-549-8117/
 (MRE)


CO: Medco Research, Inc. ST: North Carolina IN: MTC SU:

TS -- NY035 -- 2113 08/12/93 12:14 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 12, 1993
Words:314
Previous Article:ALL HONDA, ACURA MODELS TO HAVE DUAL AIRBAGS IN 1994 AS STANDARD EQUIPMENT
Next Article:TAT TECHNOLOGIES REVERSE SPLIT EFFECTIVE
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters